A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 1999

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 C4-V3 Polyvalent Peptide Vaccine

Trial Locations (3)

Vanderbilt Univ. Hosp. AVEG, Nashville

UW - Seattle AVEG, Seattle

Univ. of Rochester AVEG, Rochester

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH